Kiora Pharmaceuticals FY2025 net loss widens 401% to $11 million; revenue drops to no revenue

Reuters

Mar 25

<a href="https://laohu8.com/S/KPRX">Kiora Pharmaceuticals</a> FY2025 net loss widens 401% to $11 million; revenue drops to no revenue

FY2025 net loss swung to $10.8 million from net income of $3.6 million, on no collaboration revenue versus $16.0 million a year earlier.
FY2025 loss per share widened to $2.60 from $0.93 per share.
Q4 FY2025 net loss widened 54.76% to $6.5 million, due to a non-cash impairment charge related to KIO-104.
Q4 FY2025 R&D expenses climbed 52.63% to $2.9 million before recognizing $1.8 million in reimbursable expenses, on higher clinical trial activity for KIO-301 and KIO-104.
CEO Brian Strem said both Phase 2 trials were underway and the company expected initial clinical data in the first half of FY2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603250700NEWSFILECNPR____20260325_289753_1) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622027060"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622027060\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622027060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622027060","market":"us","top_or_hot":-1,"title":"Kiora Pharmaceuticals FY2025 net loss widens 401% to $11 million; revenue drops to no revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KPRX\">Kiora Pharmaceuticals</a> FY2025 net loss widens 401% to $11 million; revenue drops to no revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          FY2025 net loss swung to $10.8 million from net income of $3.6 million, on no collaboration revenue versus $16.0 million a year earlier.\n        </li>\n<li>\n          FY2025 loss per share widened to $2.60 from $0.93 per share.\n        </li>\n<li>\n          Q4 FY2025 net loss widened 54.76% to $6.5 million, due to a non-cash impairment charge related to KIO-104.\n        </li>\n<li>\n          Q4 FY2025 R&amp;D expenses climbed 52.63% to $2.9 million before recognizing $1.8 million in reimbursable expenses, on higher clinical trial activity for KIO-301 and KIO-104.\n        </li>\n<li>\n          CEO Brian Strem said both Phase 2 trials were underway and the company expected initial clinical data in the first half of FY2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603250700NEWSFILECNPR____20260325_289753_1) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiora Pharmaceuticals FY2025 net loss widens 401% to $11 million; revenue drops to no revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiora Pharmaceuticals FY2025 net loss widens 401% to $11 million; revenue drops to no revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KPRX\">Kiora Pharmaceuticals</a> FY2025 net loss widens 401% to $11 million; revenue drops to no revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          FY2025 net loss swung to $10.8 million from net income of $3.6 million, on no collaboration revenue versus $16.0 million a year earlier.\n        </li>\n<li>\n          FY2025 loss per share widened to $2.60 from $0.93 per share.\n        </li>\n<li>\n          Q4 FY2025 net loss widened 54.76% to $6.5 million, due to a non-cash impairment charge related to KIO-104.\n        </li>\n<li>\n          Q4 FY2025 R&amp;D expenses climbed 52.63% to $2.9 million before recognizing $1.8 million in reimbursable expenses, on higher clinical trial activity for KIO-301 and KIO-104.\n        </li>\n<li>\n          CEO Brian Strem said both Phase 2 trials were underway and the company expected initial clinical data in the first half of FY2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603250700NEWSFILECNPR____20260325_289753_1) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLc0mcDj:1","article_id":"2622027060","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622027060","pubTimestamp":1774436626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"FY2025 net loss swung to $10.8 million from net income of $3.6 million, on no collaboration revenue versus $16.0 million a year earlier.FY2025 loss per share widened to $2.60 from $0.93 per share.Q4 FY2025 net loss widened 54.76% to $6.5 million, due to a non-cash impairment charge related to KIO-104.Q4 FY2025 R&D expenses climbed 52.63% to $2.9 million before recognizing $1.8 million in reimbursable expenses, on higher clinical trial activity for KIO-301 and KIO-104.CEO Brian Strem said both Phase 2 trials were underway and the company expected initial clinical data in the first half of FY2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","KPRX":"Kiora Pharmaceuticals"},"translate_title":"Kiora Pharmaceuticals 2025财年净亏损扩大401%至1100万美元；收入下降至无收入","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPRX":0.9},"content_text":"Kiora Pharmaceuticals FY2025 net loss widens 401% to $11 million; revenue drops to no revenue\n    \n\n\n          FY2025 net loss swung to $10.8 million from net income of $3.6 million, on no collaboration revenue versus $16.0 million a year earlier.\n        \n\n          FY2025 loss per share widened to $2.60 from $0.93 per share.\n        \n\n          Q4 FY2025 net loss widened 54.76% to $6.5 million, due to a non-cash impairment charge related to KIO-104.\n        \n\n          Q4 FY2025 R&D expenses climbed 52.63% to $2.9 million before recognizing $1.8 million in reimbursable expenses, on higher clinical trial activity for KIO-301 and KIO-104.\n        \n\n          CEO Brian Strem said both Phase 2 trials were underway and the company expected initial clinical data in the first half of FY2027.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603250700NEWSFILECNPR____20260325_289753_1) on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}